MEDICLIN Aktiengesellschaft/€MED
1D1W1MYTD1Y5YMAX
Capital at risk
About MEDICLIN Aktiengesellschaft
MEDICLIN Aktiengesellschaft is a German healthcare company operating within the medical services industry. It offers a wide range of healthcare services, including rehabilitation, acute care, and nursing care, through various specialized clinics and facilities. Founded in 1993, the company is headquartered in Offenburg, Germany, and provides services primarily within the German market. MEDICLIN's strategic positioning is strengthened by its integrated care approach, allowing coordinated patient care across different treatment phases. Its broad network of facilities provides a competitive advantage in delivering comprehensive health solutions.
- Ticker
- €MED
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 7,048
- Headquarters
- Offenburg, Germany
- Website
- www.mediclin.de
MED Metrics
BasicAdvanced
€268M
9.34
€0.61
0.43
€0.04
0.70%
Price and volume
Market cap
€268M
Beta
0.43
52-week high
€5.70
52-week low
€3.00
Average daily volume
8.4K
Dividend rate
€0.04
Financial strength
Current ratio
1.773
Quick ratio
1.09
Long term debt to equity
1.358
Total debt to equity
1.469
Dividend payout ratio (TTM)
6.53%
Interest coverage (TTM)
3.32%
Profitability
EBITDA (TTM)
87.865
Gross margin (TTM)
20.92%
Net profit margin (TTM)
3.55%
Operating margin (TTM)
7.86%
Effective tax rate (TTM)
27.74%
Revenue per employee (TTM)
€120,000
Management effectiveness
Return on assets (TTM)
4.61%
Return on equity (TTM)
11.93%
Valuation
Price to earnings (TTM)
9.342
Price to revenue (TTM)
0.332
Price to book
1.03
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
5.243
Free cash flow yield (TTM)
19.07%
Free cash flow per share (TTM)
1.092
Dividend yield (TTM)
0.70%
Forward dividend yield
0.70%
Growth
Revenue change (TTM)
6.22%
Earnings per share change (TTM)
-13.68%
3-year revenue growth (CAGR)
3.76%
10-year revenue growth (CAGR)
3.70%
3-year earnings per share growth (CAGR)
34.84%
10-year earnings per share growth (CAGR)
4.62%
Bulls say / Bears say
In H1 2026, MEDICLIN achieved consolidated group revenues of €386.4 million—a 5.0% increase year-on-year—and Group EBIT rose to €26.6 million from €22.4 million, underscoring robust operational momentum. (EQS-News)
Patient volume increased to 54,708 treatments in H1 2026, up from 53,183 a year earlier, reflecting sustained demand for its rehabilitation and care services. (EQS-News)
Management reaffirmed its 2026 guidance, targeting consolidated revenue growth of 3.5%–6.5% and Group EBIT between €57.0 million and €72.0 million, highlighting confidence in its integrated care model. (EQS-News)
Staff costs rose by €9.8 million (7.2%) in H1 2026 to €145.2 million, pushing the staff cost ratio up to 55.2% and exerting pressure on margins. (EQS-News)
The Acute Care segment remained loss-making in H1 2026, with EBIT unchanged at a negative €1.1 million, signaling ongoing challenges in that division. (EQS-News)
With major shareholders Asklepios Kliniken (52.73%) and ERGO Group (35.00%) controlling over 87% of shares, MEDICLIN’s free float is just 12.27%, potentially limiting liquidity and minority shareholder influence. (MEDICLIN Annual Report 2025)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.